Professor Donna Wilcock discusses the process of going from a mouse model to human trials for testing the amyloid beta immunization for Alzheimer's disease.

Right now, as of today [November, 2008], the drug companies are in phase II and phase III clinical trials of something a little more complex than the a-beta [amyloid beta] vaccination, which is to directly administer anti-a-beta antibodies to people. The idea is that this is a safer approach than a vaccination approach because you can withdraw treatment if you see any adverse effects. So, the antibody – and we call this passive immunization – passive immunization is in phase II to phase III, and there are at the moment, to my understanding, three drug companies with three different antibodies in trials. And then the a-beta vaccination approach, which is an active vaccination, this approach is in very early phase II trials right now.

alzheimer, treatment, vaccine, immunization, phase, human, clinical, trial, antibody, vaccination, therapy, donna, wilcock